SCM
FBRX icon

Suvretta Capital Management’s Forte Biosciences FBRX Stock Holding History

Suvretta Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,678
Closed -$17.4M – 111
2021
Q2 		$17.4M Sell
20,678
-3,322
-14% -$2.99M 0.26% 64
2021
Q1 		$20.6M Buy
24,000
+11,000
+85% +$9.01M 0.3% 59
2020
Q4 		$11.8M Buy
+13,000
New +$12.2M 0.17% 58

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.88B AUM 35.68% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Suvretta Capital Management's FBRX Position: Q3 2021 in Review

Suvretta Capital Management sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 20,678 shares — an estimated $17.4M sold.

Suvretta Capital Management first reported a position in FBRX in Q4 2020 and held it in 3 quarters. The position peaked at $20.6M in Q1 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Suvretta Capital Management reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 20,678 Forte Biosciences shares in Q3 2021, an estimated $17.4M.
  • Suvretta Capital Management first reported a position in Forte Biosciences in Q4 2020 and held it in 3 quarters.
  • Suvretta Capital Management's Forte Biosciences position peaked at $20.6M in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Suvretta Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.